Business Wire

Forge Biologics Announces Regulatory Updates from FDA and EMA, Accelerating Manufacturing and Clinical Trial Momentum

Share

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that it has received additional designations and regulatory feedback from the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA), advancing the manufacturing capabilities for its own and clients’ AAV gene therapies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005324/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Forge GMP technician at The Hearth (Photo: Business Wire)

The EMA has granted orphan designation for the company’s clinical-stage gene therapy FBX-101 for the treatment of patients with Krabbe disease. FBX-101 is a first-in-human potential treatment utilizing a systemically administered adeno-associated virus (AAV) to deliver the correct version of the faulty gene responsible for an abnormality in patients with Krabbe disease, a rare and fatal genetic disorder. FBX-101 previously received Orphan Drug and Rare Pediatric Disease Designations from the FDA earlier this year.

“FBX-101 is the culmination of over 20 years of scientific research to understand the challenges faced by patients with progressive disease after hematopoietic stem cell transplantation, the current standard of care,” said Maria Escolar, M.D., Forge’s Chief Medical Officer. “We are currently recruiting patients for our RESKUE clinical trial to administer FBX-101 and we are pleased by the EMA’s designation so that patients in Europe may also have access to this potentially transformative therapeutic approach.”

The company also announced that the FDA has provided positive feedback on Forge’s AAV manufacturing processes, including use of its exclusive production plasmids and master cell bank for cGMP manufacturing of gene therapies.

Forge presented information to the FDA on its proprietary HEK293 suspension cell line, Ignition Cells™, and adenovirus helper plasmid, pEMBR™, and received FDA alignment that these technologies are suitable for cGMP manufacturing of clinical drug products.

“We are excited that the tools we have developed at Forge will help accelerate and scale cGMP production of AAV gene therapies for patients. We are thankful to have a positive dialogue with the EMA and for gaining alignment with the FDA on the suitability of our key production materials for our own and our clients’ use,” said Christopher Shilling, Vice President of Regulatory Affairs and Quality. “These new technologies can help mitigate current safety concerns surrounding critical raw materials used in AAV scale-up and production processes for programs moving from research to clinical stage.”

Forge offers “concept to clinic” AAV manufacturing and development services to accelerate gene therapy programs from preclinical stage through clinical with technology platforms enabling fully traceable cell line history for potential commercialization.

About Krabbe Disease

Krabbe disease is a rare, pediatric leukodystrophy affecting about 1-2.5 in 100,000 people in the U.S. and is inherited in an autosomal recessive manner. Krabbe disease is caused by loss-of-function mutations in the galactosylceramidase (GALC) gene, a lysosomal enzyme responsible for the breakdown of certain types of lipids such as psychosine. Without functional GALC, psychosine accumulates to toxic levels in cells. The psychosine toxicity is most severe in the myelin cells surrounding the nerves in the brain and in the peripheral nervous system, eventually leading to the death of these cells. The disease initially manifests as physical delays in development, muscle weakness and irritability and advances rapidly to difficulty swallowing, breathing and cognitive problems, and vision and hearing loss. Early onset or “Infantile” Krabbe disease cases usually results in death of patients by age 2-4 years, while later onset or “Late Infantile” cases have a more variable course of progressive decline. There is currently no approved treatment for Krabbe disease.

About FBX-101

Forge developed FBX-101 to treat patients with Infantile Krabbe disease. FBX-101 is an adeno-associated viral (AAV) gene therapy that is typically delivered after a hematopoietic stem cell transplant. FBX-101 delivers a functional copy of the GALC gene to cells in both the central and peripheral nervous system. FBX-101 has been shown to functionally correct the central and peripheral neuropathy and correct the behavioral impairments associated with Krabbe disease in animal models, as well as to drastically improve lifespan in animal models of the disease. This approach has the potential to overcome some of the immunological safety challenges observed in traditional AAV gene therapies.

About Orphan Designation

EMA orphan designation is designed to encourage the development of new treatments for life-threatening or chronically debilitating conditions that are rare (affecting not more than five in 10,000 people in the European Union). Medicines like FBX-101 that meet the EMA’s orphan designation criteria qualify for several incentives, including extended market exclusivity, protocol assistance, and potentially reduced fees for regulatory activities. The orphan designation is issued by the EMA Committee for Orphan Medicinal Products (COMP) for use in the European Union.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 square foot facility in Columbus, Ohio, The Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.

For more information, please visit https://www.forgebiologics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Families and Clinician Inquiries
Dr. Maria Escolar
Chief Medical Officer
medicalaffairs@forgebiologics.com

Business Development
Magdalena Tyrpien
Vice President and Head, Business Development
BD@forgebiologics.com

Client Development
John Maslowski
Chief Commercial Officer
CD@forgebiologics.com

Investor Relations
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations
Investors@forgebiologics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EUMETSAT: Europe’s First Geostationary Sounder Satellite Is Launched2.7.2025 14:20:00 EEST | Press release

Europe has taken a major step forward in strengthening its resilience to extreme weather events with the successful launch of the Meteosat Third Generation Sounder 1 (MTG-S1) satellite. MTG-S1 will deliver new streams of atmospheric data, enabling earlier, more accurate warnings that protect lives, property and infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702002782/en/ MTG-S1 is part of the Meteosat Third Generation programme, Europe’s new fleet of geostationary meteorological satellites. Image: EUMETSAT Extreme weather events like storms, flooding, and heatwaves have caused hundreds of billions of euros in damage and claimed tens of thousands of lives across Europe in the past decades. Launched on 1 July 2025, MTG-S1 will provide Europe’s national meteorological services with high-frequency data on temperature, humidity and trace gases throughout the atmosphere – enabling forecasters to detect the earli

HCLTech and Equinor Expand Digital Collaboration2.7.2025 14:08:00 EEST | Press release

HCLTech, a global technology leader, and Equinor, Europe's largest energy supplier and a pioneer in renewables and low-carbon solutions, have expanded their IT collaboration to support the next phase of Equinor’s digital transformation. This expanded relationship will cover Equinor’s IT landscape across several key strategic areas. HCLTech will support Equinor as it accelerates its digital transformation by: Accelerating its cloud migration and standardizing services across operations Enhancing its cyber resilience and network performance Improving workplace experience through automation Enabling advanced user experiences with technologies like augmented reality (AR) "We’re pleased to continue our long-standing collaboration with Equinor," said Sandeep Kumar Saxena, Executive Vice President, HCLTech. "This collaboration reflects our shared commitment to innovation and sustainability.” Over the past decade, HCLTech has been a trusted advisor to Equinor, supporting the company’s global e

Wizz Air Tops Major Airline Emissions Rankings2.7.2025 12:00:00 EEST | Press release

Wizz Air is the world's most emissions-efficient airline in new rankings released today by Cirium, the aviation analytics firm. The Cirium Flight Emissions Review ranks the top 20 airlines globally, through a consistent benchmark for flight emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702342529/en/ The top 20 Major airlines globally, ranked by lowest CO2/ASK Wizz Air, the Hungary-based ultra-low-cost airline emits an industry low of 53.9 grams of CO₂ per Available Seat Kilometer (ASK)*, followed by Frontier Airlines (54.4 grams) and Pegasus (57.1 grams) according to the report. The rankings provide the aviation industry with verified comparable data on an equal playing field as the sector advances toward Net Zero by 2050 commitments. The rankings performance use Cirium's EmeraldSky platform, which achieved ISAE 3000 Reasonable Assurance from PricewaterhouseCoopers (PwC) and official accreditation from the Roc

L&T Technology Services Chosen by TRATON GROUP as Strategic Engineering Partner in Global R&D Transformation2.7.2025 11:59:00 EEST | Press release

L&T Technology Services (BSE: 540115, NSE: LTTS), today announced that it has been chosen by the TRATON GROUP, one of the world’s leading manufacturers of commercial vehicles, as a strategic engineering partner. This collaboration in LTTS’ Mobility segment will support TRATON’s roadmap to build a unified, future-ready product-development platform that delivers scale, speed, and sustainable mobility solutions worldwide. TRATON is reshaping its global R&D ecosystem to unlock cross-brand synergies while expanding the share of battery-electric vehicles in line with its 2029 profitability and sustainability targets. LTTS’ selection will see the company provide engineering support, from mechanical and software engineering to digital systems integration - across key development hubs in Sweden, Germany, the United States, Poland, and India. The collaboration positions LTTS to deepen existing workstreams and pursue new programs across TRATON’s brands, spanning software-defined vehicle architect

Nexo Becomes First-Ever Digital Wealth Platform of the DP World Tour, Launches Nexo Championship2.7.2025 11:30:00 EEST | Press release

Nexo, the premier digital assets wealth platform, has signed a three-year landmark partnership with the DP World Tour, becoming an Official Marketing Partner and the Tour’s Official Digital Wealth Platform through 2027. This agreement marks the first-ever multi-year partnership between a digital assets company and a major global golf tour — a historic convergence of crypto and golf — reflecting both organizations’ shared commitment to performance, innovation, and a global outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702770847/en/ Nexo becomes the first-ever Official Digital Wealth Platform of the DP World Tour. Nexo has also become the Title Partner of the newly renamed Nexo Championship — previously the Scottish Championship — taking place from August 7–10, 2025. The tournament is set at the Trump International Golf Links in Aberdeenshire, which has earned a reputation as one of the finest modern links courses

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye